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Abstract Sparassis crispa (S. crispa) is a mushroom used
as a natural medicine that recently became cultivatable in
Japan. In this study, we investigated not only the pre-
ventive effects of S. crispa against stroke and hypertension
in stroke-prone spontaneously hypertensive rats (SHRSP)
but also the mechanism involved by using studies of the
cerebral cortex at a young age. Six-week-old male SHRSP
were divided into 2 groups, a control group and an S. crispa
group administered 1.5% S. crispa in feed, and we then
observed their survival. In addition, rats of the same age
were treated with 1.5% S. crispa for 4 weeks and we
measured body weight, blood pressure, blood ﬂow from the
tail, NOx production, and the levels of expression of sev-
eral proteins in the cerebral cortex by western blot analysis.
Our results showed that the S. crispa group had a delayed
incidence of stroke and death and signiﬁcantly decreased
blood pressure and increased blood ﬂow after the admin-
istration. Moreover, the quantity of urinary excretion and
the nitrate/nitrite concentration in cerebral tissue were
higher than those of control SHRSP rats. In the cerebral
cortex, phosphor-eNOS (Ser1177) and phosphor-Akt
(Ser473) in S. crispa-treated SHRSP were increased com-
pared with those of control SHRSP rats. In conclusion,
S. crispa could ameliorate cerebrovascular endothelial
dysfunction by promoting recovery of Akt-dependent
eNOS phosphorylation and increasing NO production in
the cerebral cortex. S. crispa may be useful for preventing
stroke and hypertension.
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Introduction
One of the main causes of stroke is hypertension.
In patients with long-term hypertension, functional modi-
ﬁcations in the cerebrovascular system have also been
found [1]. Therefore, it is important to avoid high blood
pressure as a preventative measure. Hypertensive drug
therapy is an easy recently developed approach that can
reduce blood pressure by the administration of an antihy-
pertensive agent. However, there is a risk of side effects
and the treatment lasts for a long time. This explains the
utility of blood pressure control by selection of appropriate
food for which there are few side effects.
The medical and pharmacological effects of mushrooms
have been shown to vary greatly in terms of antihyperten-
sion, antitumor, and antidiabetic properties as well as those
against various other diseases [2]. Some mushrooms have
been used in Chinese medicine and folk medicine for a long
time. Recently published reports have demonstrated that
variouskindsofmushroomshavebeneﬁcialeffectsonblood
pressure [3–6]. Sparassis crispa (S. crispa) is an edible
mushroom that has recently been cultivated in Japan. It
contains a remarkably high concentration of beta-glucan,
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DOI 10.1007/s11418-010-0475-9which exhibits antitumor [7] and antidiabetic [8] activities.
However, there have not yet been any detailed studies of the
effects of S. crispa on hypertension and stroke.
Stroke-prone spontaneously hypertensive rats (SHRSP),
a substrain of SHR created by selective breeding, have
become a model for basic research on hypertension-asso-
ciated cerebrovascular injury, because this model (SHRSP)
presents with marked elevation of blood pressure and
almost all of these animals develop stroke. Numerous
nutritional and pathological studies using SHRSP have
revealed that various foods are protective against hyper-
tension and stroke [9, 10].
The present study investigated whether S. crispa
exhibits preventive effects against hypertension and stroke
and the mechanisms behind such effects by using SHRSP.
Methods
Animals
Study 1
Six-week-old male SPF (speciﬁc pathogen free) stroke-
prone spontaneously hypertensive rats (SHRSP) were
purchased from Japan SLC (Shizuoka, Japan). All rats were
housed in a climate-controlled (temperature 22–24C,
humidity 40–60%) light-regulated room with a 12-h light
and dark cycle. SHRSP were separated into 2 groups
(n = 8–9): a control group (not treated) and an S. crispa
group (administered 1.5% S. crispa, which was supplied by
Katsuragi Industry Co., Ltd., Japan). All groups consumed
an SP diet (Funahashi Co., Tokyo, Japan) and had free
accesstoratchowandwaterthroughouttheexperiment.The
survival rate of the rats was determined. Autopsies were
conducted on the day of death and all rats were checked for
stroke at the brain. All procedures were carried out in
accordance with the guiding principles for the care and use
of animals in the ﬁeld of physiological sciences established
by the Physiological Society of Japan and the guidelines for
the care and use of animals set by Mukogawa University.
Study 2
MaleSHRSPat6 weeksofageweredividedinto2groups:a
control group and an S. crispa group administered 1.5%
S.crispa(n = 8each).Allratswerehousedasinstudy1.We
measured daily water and food intakes of the rats. Body
weight and blood pressure were measured every 2 weeks.
Blood ﬂow of venous microcirculation in the tail was mea-
sured before and after 4 weeks of treatment. At the conclu-
sionofthe4-weektreatmentperiod,24-hurinesampleswere
collected by placing the rats in metabolic cages. Food was
withdrawn, but water was provided. Then, the animals were
anesthetized with intraperitoneal injections of pentobarbital
sodium (Nembutal, 100 mg/kg). The tissues were immedi-
ately harvested and cleaned for measurement of tissue
weight, and brain was promptly frozen in liquid nitrogen for
analysis. The samples were then stored at -80C.
Blood pressure measurements
Systolic blood pressure (SBP) was measured by using a
sphygmomanometer (UR-1000, Ueda Co., Chiba) using the
tail-cuff method. An average of 3 measurements were
taken as the initial mean SBP.
Blood ﬂow measurements
The blood ﬂow through the venous microcirculation in the
tail was monitored by using a laser Doppler blood ﬂow
meter of the contact type (FLO-C1, Muromachi, Tokyo).
Brieﬂy, all rats were pre-warmed at 36C and blood ﬂow
was measured while keeping the animal at 36Co na
holder. The rate of change in blood ﬂow was calculated as
follows: Rate of change = (blood ﬂow before treatment/
blood ﬂow after treatment) 9 100.
Urinary and cerebral nitrate/nitrite assay
Samples of cerebral cortex were obtained by homogeni-
zation with twofold methanol followed by centrifugation at
3,000 rpm for 5 min; urinary samples were also centri-
fuged under the same conditions, and supernatants were
then analyzed. Nitrate and nitrite (NOx) concentrations in
the urine and cerebral cortex were measured by the Griess
method using an automated NO detector high-performance
liquid chromatography system (ENO-20, Eicom, Kyoto) as
described previously [11].
Primary antibodies used
Immunoblotting was performed with the following com-
mercially available antibodies: anti-rabbit eNOS from
Afﬁnity BioReagents Inc. (golden); anti-rabbit phospho-
eNOS (Ser1177), anti-rabbit Akt, anti-rabbit phospho-Akt
(Ser473, Thr308), anti-rabbit mTOR, anti-rabbit phospho-
mTOR (Ser2448), and anti-rabbit nNOS from Cell
Signaling Technology (Beverly, MA). Anti-mouse b-actin
and anti-rabbit iNOS were obtained from Sigma (St. Louis,
MO, USA).
Western blot analysis
The cerebral cortex was homogenized with ice-cold
homogenized buffer containing 50 mM Tris–HCl (pH 7.4),
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0.1% SDS, 1 mM EDTA, 50 mM NaF, 2 mM Na3VO4,
30 mM Na pyrophosphate, 2 mM phenylmethylsulfonyl
ﬂuoride (PMSF), 1 mM benzamidine, 0.02 g/mL trypsin
inhibitor, 0.02 g/mL leupeptin, and 0.02 g/mL aprotinin.
After incubation for 2 h, lysates were centrifuged at
15,000 rpm for 20 min and supernatants were isolated.
Proteins were extracted by boiling the tissues in 0.5 mmol/l
Tris/HCl, pH 6.8, glycerol, 10% SDS, 0.1% bromophenol
blue, and 2-mercaptoethanol. The proteins (25 lg) were
electrophoresed by using 7.5–12.5% SDS-PAGE gel at
100 V for 2 h. After fractionating, the proteins were trans-
ferred onto a poly(vinylidene diﬂuoride) (PVDF) membrane
(Amersham Inc. Buckinghamshire) at 100 mA for 2 h. The
membrane was blocked in Blocking One (Nacalai Tesque,
Kyoto) for 20 min. After appropriate blocking, the blot was
incubated with anti-iNOS(1:5,000), anti-nNOS, anti-eNOS,
anti-phospho-eNOS (Ser1177), anti-Akt, anti-phospho-Akt
(Ser473andThr308),anti-mTOR,andanti-phosphormTOR
(1:1,000) in antibody solution 1 (Toyobo, Osaka) overnight.
It was then washed with Tris-buffered saline (TTBS) and
ﬁnally incubated for 1 h with a 1:5,000 dilution of anti-
rabbit and mouse IgG–horseradish peroxidase. Detection
was achieved by using an ECL kit (Amersham Inc.
Buckinghamshire). b-actin was used as an internal control.
Thedensityofthebands wasmeasured byusingNIHImage.
Statistical analysis
Data are expressed as the mean ± SEM. Cumulative sur-
vival was analyzed for differences according to Kaplan–
Meier followed by Wilcoxon test. Statistical analysis of the
data was performed by Student’s t test to determine the
signiﬁcance of differences. A p value of less than 0.05 was
considered signiﬁcant.
Results
Intakes of water and food, and volume of urine
Water and food intakes over the 4-week period of the study
did not differ between the control group and the S. crispa
group. In addition, no difference was observed in terms of
the volume of urine between the two groups (Table 1).
Survival rate, blood pressure, and body weight
Kaplan–Meier survival curves revealed that rats in the
S. crispa group had a signiﬁcantly higher survival rate than
rats in the control group (Fig. 1). Moreover, SHRSP rats
treatedwithS.crispashowedsigniﬁcantinhibitionoftherise
in blood pressure after 2 and 4 weeks of oral administration
(Fig. 2a). However, body weight did not differ between the
SHRSP group and the S. crispa group (Fig. 2b).
Change in blood ﬂow and NO production
The change in the amount of blood ﬂow in venous
microcirculation in the tail after treatment is shown in
Fig. 3a. The administration of S. crispa signiﬁcantly
increased blood ﬂow compared with that in the control
group. In addition, 24-h urinary NO metabolite (nitrate and
nitrite) excretion and concentration in the cerebral cortex in
the S. crispa group was 2–3-fold higher than that in the
control group (Fig. 3b, c). None of these changes reached
signiﬁcance, but these experimental data correspond to the
blood pressure and blood ﬂow data.
Measurement of tissue weight
Table 2 shows the ratio of tissue weight to body weight.
There were no signiﬁcant differences in this ratio between
the control group and the S. crispa group at 4 weeks after
administration.
Various types of NOS protein expression
To investigate whether expressions of synthases for NO,
which are vasodilators, showed any differences between
Table 1 Water, food intake and urinary extract volume at 4 weeks
after administration
Water intake (mL) Food intake (g) Urinary volume (mL)
Control 21.50 ± 4.54 18.60 ± 0.19 19.08 ± 3.67
S. crispa 25.67 ± 4.25 18.47 ± 0.53 19.00 ± 1.98
Data are means ± SEM n = 6
Fig. 1 Kaplan–Meier survival curves showing that SHRSP admin-
istered S. crispa had a signiﬁcantly higher survival rate than the
control group (Wilcoxon test)
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bodies to measure iNOS, nNOS, and eNOS. We deter-
mined that SHRSP receiving S. crispa did not show any
changes in these protein levels (Fig. 4).
Effects of phosphorylation of eNOS via PI3 K/Akt
pathway
The level of phosphorylation of eNOS at Ser1177 in the
cerebralcortexoftheS.crispagroupwassigniﬁcantlyhigher
than that in the control group, as determined by western
blotting with phosphospeciﬁc antibody (Fig. 5d). Because
activation of the serine/threonine kinase Akt phosphorylates
and activates eNOS, which in turn induces NO production
and vasorelaxation, the phosphorylation of Akt was also
studied. The results of western blot analysis demonstrated
that cerebral cortex expression of Akt phosphorylated at
Ser473 was signiﬁcantly induced in the S. crispa group
compared with that in the control group (Fig. 5b). Immu-
noblot analysis with antibodies against total Akt showed
equalprotein levels inallgroups,thus demonstrating thatthe
induced amount of phosphor-Akt (Ser473) was not due to
increased expression of Akt (Fig. 5a). In addition, there was
no difference in Thr308 between the two groups (Fig. 5c).
Effects of phosphorylation of mTOR
Although mTOR is located downstream of Akt, the ratio of
phosphor-mTOR (Ser2448) to total mTOR did not differ
between the control group and the S. crispa group
(Fig. 5e).
Discussion
The major ﬁndings of the present study are as follows: (1)
The administration of Sparassis crispa (S. crispa)t o
SHRSP from a young age improves survival and reduces
Fig. 2 Effect of S. crispa on systolic blood pressure and body weight:
control group (n = 8) and S. crispa group (n = 8). All values are the
means ± SEM; *p\0.01 versus control group (Student’s t test)
Fig. 3 a Measurement of blood ﬂow in the tail of rats in the control
group (n = 8) and the S. crispa group (n = 8) before and after
administration. The rate of change in blood ﬂow is expressed as a
percentage relative to the value before treatment. b Urinary nitrate/
nitrite (NOx) excretion and c cerebral nitrate/nitrite (NOx) concen-
tration at 4 weeks after administration. Control group (n = 4) and
S. crispa group (n = 4). Data are means ± SEM; *p\0.01 versus
control group (Student’s t test)
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123the elevation of blood pressure. (2) The mechanism for
this action was improvement of endothelial dysfunction
via increases in NO production with activation of the
Akt/eNOS signaling pathway on vessel cerebral cortex.
The SHRSP is a model of essential hypertension in
humans, and was developed from SHR demonstrating
abnormalities of the renin-angiotensin system, catechola-
mines, vasopressin, and vasoactive intestinal peptide [12].
It is well known that blood pressure in SHRSP is already
signiﬁcantly higher than that in WKY, a normal blood
pressure rat, at a young age and that almost all SHRSP
develop stroke. Moreover, a signiﬁcant decrease in regio-
nal cerebral blood ﬂow in SHRSP frontal cortex at 6 weeks
of age compared with that in WKY was observed [13]. The
data presented in our survival studies clearly showed that
S. crispa protected SHRSP against stroke death. Further-
more, the administration of S. crispa was associated with
an inhibition of elevated blood pressure and a restoration of
impaired peripheral blood ﬂow, which indicates that
S. crispa may improve vascular function including that in
brain blood vessels.
Nitric oxide (NO) plays an important role in the mod-
ulation of vascular tone and structure. In animal models of
hypertension and patients with hypertension, nitric oxide
(NO) production is abnormal, leading to hypertensive
vascular lesion formation [14]. NO in the brain inhibits
sympathetic nerve activity [15, 16] or directly affects
vasodilatation via a cGMP mechanism, thereby reducing
blood pressure [17–19]. The present study showed that
S. crispa induced a higher level of NOx in the cerebral
cortex compared with that in the control group.
It is well known that NO is generated by nitric oxide
synthases (NOSs), which have three distinct isoforms. NO
from endothelial NOS (eNOS) when present in vessel
endothelial cells is known to regulate vascular tone, while
neuronal NOS (nNOS) is involved in neural signaling,
and inducible NOS (iNOS) modulates immune function
[20–22]. Our study suggests that none of the types of NOS
showed any differences in expression between the control
group and the S. crispa group at 4 weeks after adminis-
tration. In particular, of all NOS types, NO generation from
eNOS would initially limit stroke and brain injury by
inducing vasodilation [23]. We previously reported that
eNOS activity plays an important role in vasodilation,
rather than eNOS expression, at a younger age in the
SHRSP strain. The enzymatic activity of eNOS is regulated
by phosphorylation at Ser1177, and one of the kinases that
mediates phosphorylation of eNOS is Akt, which has an
activation process involving two phosphorylation sites,
Ser473 and Thr308, by phosphoinositide-dependent protein
kinases [24]. Our previous study also demonstrated that
phosphorylation of eNOS and Akt was decreased in the
cerebral cortex of SHRSP compared with that in WKY.
Interestingly, S. crispa restored eNOS phosphorylation,
which was markedly impaired in the cerebral cortex of
SHRSP, and this improvement was associated with the
recovery of Akt, especially at the site of Ser473 phos-
phorylation. Enhanced Akt/eNOS signaling upon the
Table 2 Effects of S. crispa on tissue weight (g/100 g body weight)
Tissues Control (n = 6) S. crispa (n = 6)
Brain 0.60 ± 0.04 0.57 ± 0.02
Heart 0.47 ± 0.04 0.44 ± 0.03
Spleen 0.22 ± 0.01 0.22 ± 0.01
Liver 3.39 ± 0.12 3.18 ± 0.10
Kidney 0.85 ± 0.03 0.82 ± 0.03
Adrenal gland 0.02 ± 0.00 0.02 ± 0.00
Testis 1.20 ± 0.07 1.14 ± 0.04
Values are means ± SEM
Fig. 4 Western blot analysis of the protein expression of iNOS (a),
nNOS (b), and eNOS (c) in the cerebral cortex at 4 weeks after
administration. b-actin served as protein quantity control in each
experiment. Control group (n = 4) and S. crispa group (n = 4). Data
are means ± SEM (Student’s t test)
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tion of elevated blood pressure, restoration of impaired
blood ﬂow, and increased NOx in the cerebral cortex.
In contrast to eNOS, the mammalian target of rapa-
mycin (mTOR), which is also downstream of Akt, is an
important molecule in the regulation of protein synthesis
and cell growth, and mTOR activity also requires
phosphorylation at Ser2448 by Akt. Many neurodegen-
erative diseases are characterized by neuronal death via
apoptosis, and it is possible that modulation of mTOR
activity may offer some protection against these effects
[24]. In particular, diseases involving oxygen and nutri-
ent deprivation, such as stroke, would be expected to be
associated with inhibition of the mTOR pathway [25].
Moreover, previous studies have demonstrated that focal
ischemic brain injury signiﬁcantly decreases the levels of
phosphorylated Akt and mTOR, and suppresses protein
synthesis [26]. We expected activation of mTOR with
the increase in phosphor-Akt due to the administration of
S. crispa; however, no such effect was observed. In
brief, upon the administration of S. crispa, there is only
improvement of Akt/eNOS signaling without an effect on
mTOR in SHRSP brain.
Many mushrooms have been reported to exhibit anti-
hypertension effects. It has been reported that mushroom
species such as Lentinula edodes, Ganoderma lucidum,
Grifola frondosa, Pleurotus cornucopiae, and Pleurotus
nebrodensis have antihypertension activities; moreover,
their mechanisms of action have been suggested to involve
the decrease blood pressure by improvement in blood
levels of triglyceride and cholesterol as well as kidney
function and inhibition of angiotensin-converting enzymes
[3, 4, 27, 28]. However, this is the ﬁrst report to indicate an
antihypertensive mechanism involving an improvement in
endothelial signaling due to mushrooms.
In conclusion, long-term hypertension has been impli-
cated in functional modiﬁcations in the cerebrovascular
system and causes of stroke. Therefore, it is important to
avoid high blood pressure as a preventative measure.
S. crispa can delay stroke through restoration of cerebro-
vascular endothelial dysfunction via enhancement of the
Akt/eNOS/NO system in the cerebral cortex of SHRSP.
This suggests that S. crispa may have utility as a functional
food for the prevention of hypertension and stroke;
moreover, novel components from this mushroom may be
discovered in the future.
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